Drug Evaluation Data

Abstract

Get full access to this article

View all access options for this article.

References

Clarkson

: The Physiologic Disposition of 5-Fluorouracil and 5-Fluoro-2′-deoxyuridine in Man, Clinical Pharmacol. Therap. 5: 581–610 (Sept.-Oct.) 1964.

Floxuridine, (FUDR) package circular, (Feb.) 1971.

Burrows

J. H.

: Infusion of Fluorourinated Pyrimidines into Hepatic Artery for Treatment of Metastatic Carcinoma of Liver, Cancer 20 (11): 1886 (Nov.) 1967.

Sullivan

R. D.

: The Clinical Effects of the Continuous Intravenous and Intra-Arterial Infusion of Cancer Chemotherapeutic Compounds, Cancer Chemotherapy Rept. 16: 499–510 (Feb.) 1962.

Ansfield

F. J.

: A Preliminary Comparison of 5-Fluoro-2′-deoxyuridine Administered by Rapid Daily Intravenous Injections and by Slow Continuous Infusions, Cancer Chemotherapy Rept. 16: 389–390 (Feb.) 1962.

Moertel

C. G.

Reitemeier

R. J.

Hahn

R. G.

: Fluorinated Pyrimidine Therapy of Advanced Gastrointestinal Cancer, Gastroenterology 46: 371–378 (Apr.) 1964.

Mukherjee

K. L.

: Studies on Fluorinated Pyrimidines XVI. Metabolism of 5-Fluorouracil-2-C14 and 5-Fluoro-2′-deoxyuridine-2-C14 in Cancer Patients, Cancer Res. 23: 49–66 (Jan.) 1963.

Wilson

W. L.

: Further Clinical Evaluation of 2′ − Deoxy − 5 − Fluorouridine (NSC-27640) Cancer Chemotherapy Rept. 51: 85–90 (Apr.) 1967.

Sullivan

R. D.

Miller

: The Clinical Effects of Prolonged Intravenous Infusion of 5-Fluoro-2′-deoxyuridine, Cancer Res. 25: 1025–1030 (Aug.) 1965.

10.

Serlin

: Use of 5-Fluorodeoxyuridine (FUDR) as an Adjuvant to the Surgical Management of Carcinoma of the Stomach, Cancer 24: 223–228 (Aug.) 1969.

11.

Ansfield

F. J.

: Ineffectiveness of 5-Fluoro-2′-deoxyuridine in Man After Failure of 5-Fluorouracil, Cancer Chemotherapy Rept. 28: 47–48 (Apr.) 1963.

12.

Reitemeier

R. J.

: Comparison of 5-Fluorouracil (NSC-19893) and 2′-Deoxy-5-Fluorouridine (NSC27640) in Treatment of Patients with Advanced Adenocarcinoma of Colon or Rectum, Cancer Chemotherapy Rept. 44: 39–43 (Feb.) 1965.

13.

Ansfield

F. J.

Curreri

A. R.

: Further Clinical Comparison Between 5-Fluorouracil (5-FU) and 5-Fluoro-2′-deoxyuridine (5-FUdR), Cancer Chemotherapy Rept. 32: 101–105 (Oct.) 1963.

14.

Eastern Cooperative Group in Solid Tumor Chemotherapy: Comparison of Antimetabolites in the Treatment of Breast Cancer and Colon Cancer, J. Am. Med. Assoc. 200: 770–778 (May) 1967.

15.

Couture

Deschenes

Poulin

: Utilization de l'Amethopterine et de la Floxuridine en Infusion Intraarterielle dans le Traitement des Tumeurs de la Tete et du Cou, Un. Med. Canada 99: 1110–1112 (June) 1970.

16.

Curreri

A. R.

Ansfield

F. J.

: Comparison of 5-Fluorouracil and 5-Fluoro-2′-deoxyuridine in the Treatment of Far-Advanced Breast and Colon Lesions, Cancer Chemotherapy Rept. 16: 387–338 (Feb.) 1962.

17.

Moertel

C. G.

: Cerebellar Ataxia Associated with Fluorinated Pyrimidine Therapy, Cancer Chemotherapy Rept. 41: 15–18 (Sept.) 1964.

18.

Wolberg

W. H.

: Studies on the Mechanism of Human Tumor Resistance to the Fluorinated Pyrimidines, Cancer Res. 24: 1437–1447 (Sept.) 1964.

19.

Moertel

C. G.

Reitemeier

R. J.

: Chemotherapy of Gastrointestinal Cancer, Surg. Clin. N. Amer. 47: 929–953 (Sept.) 1967.

20.

Moertel

C. G.

: A Controlled Comparison of 5 − Fluoro − 2′ − deoxyuridine Therapy Administered by Rapid Intravenous Injection and by Continuous Intravenous Infusion, Cancer Res. 27: 549–552 (Mar.) 1967.

21.

Moertel

C. G.

Reitemeier

R. J.

: A Controlled Comparison of Intravenous 5-FUDR Therapy Administered by Continuous Infusion and by Rapid Injection, Proc. Am. Assoc. Cancer Res. 7 (4): 50 (Apr.) 1966.